Hepatitis C drug development at a crossroads
David R. Nelson – 28 September 2009
David R. Nelson – 28 September 2009
Alexander L. Gerbes, Dieter Jüngst – 28 September 2009
Hayato Hikita, Tetsuo Takehara, Satoshi Shimizu, Takahiro Kodama, Wei Li, Takuya Miyagi, Atsushi Hosui, Hisashi Ishida, Kazuyoshi Ohkawa, Tatsuya Kanto, Naoki Hiramatsu, Xiao‐Ming Yin, Lothar Hennighausen, Tomohide Tatsumi, Norio Hayashi – 28 September 2009 – Anti‐apoptotic members of the Bcl‐2 family, including Bcl‐2, Bcl‐xL, Mcl‐1, Bcl‐w and Bfl‐1, inhibit the mitochondrial pathway of apoptosis. Bcl‐xL and Mcl‐1 are constitutively expressed in the liver.
Johannes Wiegand, Keyur Patel, Hans L. Tillmann – 28 September 2009
Maurizia R. Brunetto – 28 September 2009
Antonio Mazzocca, Emilia Fransvea, Gabriela Lavezzari, Salvatore Antonaci, Gianluigi Giannelli – 28 September 2009 – Curative therapies for patients with hepatocellular carcinoma (HCC) are mainly invasive, and with the exception of sorafenib, no medical treatments are available for advanced or metastatic stages of HCC. We investigated the antitumoral effect of blocking the transforming growth factor β (TGF‐β) signaling pathway in HCC with LY2109761, a kinase inhibitor of TGF‐β receptor I kinase.
Jasmohan S. Bajaj, Kia Saeian, Christine M. Schubert, Muhammad Hafeezullah, Jose Franco, Rajiv R. Varma, Douglas P. Gibson, Raymond G. Hoffmann, R. Todd Stravitz, Douglas M. Heuman, Richard K. Sterling, Mitchell Shiffman, Allyne Topaz, Sherry Boyett, Debulon Bell, Arun J. Sanyal – 28 September 2009 – Patients with minimal hepatic encephalopathy (MHE) have impaired driving skills, but association of MHE with motor vehicle crashes is unclear. Standard psychometric tests (SPT) or inhibitory control test (ICT) can be used to diagnose MHE.
Alberto Quaglia, Ahlam Mustafa, Ragai R. Mitry, Bernard Portmann – 28 September 2009
23 September 2009
23 September 2009